J Korean Med Sci.  2021 Jan;36(4):e27. 10.3346/jkms.2021.36.e27.

Clinical Practice Guidelines for Prenatal Aneuploidy Screening and Diagnostic Testing from Korean Society of Maternal-Fetal Medicine:(1) Prenatal Aneuploidy Screening

• Choe SA
• Seol HJ
• Kwon JY
• Park CW
• Kim M
• Lee JY
• Kim MA
• Hwang HS
• Na S
• Shim JY
• Kim K
• Ryu HM

• KMID: 2511632
• DOI: http://doi.org/10.3346/jkms.2021.36.e27

Abstract

In 2019, the Korean Society of Maternal-Fetal Medicine developed the first Korean clinical practice guidelines for prenatal aneuploidy screening and diagnostic testing. These guidelines were developed by adapting established clinical practice guidelines in other countries that were searched systematically, and the guidelines aim to assist in decision making of healthcare providers providing prenatal care and to be used as a source for education and communication with pregnant women in Korea. This article delineates clinical practice guidelines specifically for maternal serum screening for fetal aneuploidy and cell-free DNA (cfDNA) screening. A total of 19 key questions (12 for maternal serum and 7 for cfDNA screening) were defined. The main recommendations are: 1) Pregnant women should be informed of common fetal aneuploidy that can be detected, risks for chromosomal abnormality according to the maternal age, detection rate and false positive rate for common fetal aneuploidy with each screening test, limitations, as well as the benefits and risks of invasive diagnostic testing, 2) It is ideal to give counseling about prenatal aneuploidy screening and diagnostic testing at the first prenatal visit, and counseling is recommended to be given early in pregnancy, 3) All pregnant women should be informed about maternal serum screening regardless of their age, 4) cfDNA screening can be used for the screening of trisomy 21, 18, 13 and sex-chromosome aneuploidy. It is not recommended for the screening of microdeletion, 5) The optimal timing of cfDNA screening is 10 weeks of gestation and beyond, and 6) cfDNA screening is not recommended for women with multiple gestations. The guideline was reviewed and approved by the Korean Academy of Medical Sciences.

Keyword

Aneuploidy; Down Syndrome; Korea; Maternal Serum Screening; Cell-free DNA Screening; Practice Guideline; Prenatal Diagnosis

Reference

1. KSIS. Fertility rate by maternal age (1999–2019). Updated 2020. Accessed August 8, 2020. http://kosis.kr/statisticsList/statisticsListIndex.do?menuId=M_01_01&vwcd=MT_ZTITLE&parmTabId=M_01_01#SelectStatsBoxDiv.

2. Resta RG. Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: implications for prenatal screening and genetic counseling. Am J Med Genet A. 2005; 133A(1):31–36. PMID: 15637725.

3. Hook EB, Cross PK, Schreinemachers DM. Chromosomal abnormality rates at amniocentesis and in live-born infants. JAMA. 1983; 249(15):2034–2038. PMID: 6220164.

4. Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet. 1998; 62(4):768–775. PMID: 9529358.

5. Cunningham FG, Leveno KJ, Bloom SL, Dashe JS, Hoffman BL, Casey BM, et al. Williams Obstetrics. 25th ed. New York, NY: McGraw-Hill Education;2018.

6. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997; 350(9076):485–487. PMID: 9274585.

7. Jo MW, Lee JY, Kim NS, Kim SY, Sheen S, Kim SH, et al. Assessment of the quality of clinical practice guidelines in Korea using the AGREE Instrument. J Korean Med Sci. 2013; 28(3):357–365. PMID: 23487579.

8. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999; 64(1):218–224. PMID: 9915961.

9. Taylor-Phillips S, Freeman K, Geppert J, Agbebiyi A, Uthman OA, Madan J, et al. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ Open. 2016; 6(1):e010002.

10. Pös O, Budiš J, Szemes T. Recent trends in prenatal genetic screening and testing. F1000 Res. 2019; 8:F1000 Faculty Rev-764.

11. Noh JJ, Ryu HM, Oh SY, Choi SJ, Roh CR, Kim JH. A two-year experience of non-invasive prenatal testing (NIPT) at an urban tertiary medical center in South Korea. Taiwan J Obstet Gynecol. 2019; 58(4):545–551. PMID: 31307749.

12. Kim SH, Kim KW, Han YJ, Lee SM, Lee MY, Shim JY, et al. Korean physicians' attitudes toward the prenatal screening for fetal aneuploidy and implementation of non-invasive prenatal testing with cell-free fetal DNA. J Genet Med. 2018; 15(2):72–78.

13. Lee DE, Kim H, Park J, Yun T, Park DY, Kim M, et al. Clinical validation of non-invasive prenatal testing for fetal common aneuploidies in 1,055 Korean pregnant women: a single center experience. J Korean Med Sci. 2019; 34(24):e172. PMID: 31222985.

14. Redman CW, Dollery E, Jordan JA. Development of the European colposcopy core curriculum: use of the Delphi technique. J Obstet Gynaecol. 2004; 24(7):780–784. PMID: 15763789.

15. Committee on Practice Bulletins—Obstetrics, Committee on Genetics, and the Society for Maternal-Fetal Medicine. Practice Bulletin No. 163: Screening for Fetal Aneuploidy. Obstet Gynecol. 2016; 127(5):e123–37. PMID: 26938574.

16. The Canadian Early and Mid-trimester Amniocentesis Trial (CEMAT) Group. Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis. Lancet. 1998; 351(9098):242–247. PMID: 9457093.

17. Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2015; 45(3):249–266. PMID: 25639627.

18. Porreco RP, Garite TJ, Maurel K, Marusiak B, Ehrich M, van den Boom D, et al. Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA. Am J Obstet Gynecol. 2014; 211(4):365.e1–365.e12. PMID: 24657131.

19. Wald NJ, White N, Morris JK, Huttly WJ, Canick JA. Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening. Br J Obstet Gynaecol. 1999; 106(12):1304–1306. PMID: 10609726.

20. Bromley B, Lieberman E, Shipp TD, Benacerraf BR. The genetic sonogram: a method of risk assessment for Down syndrome in the second trimester. J Ultrasound Med. 2002; 21(10):1087–1096. PMID: 12369663.

21. Nyberg DA, Souter VL. Use of genetic sonography for adjusting the risk for fetal Down syndrome. Semin Perinatol. 2003; 27(2):130–144. PMID: 12769199.

22. Neveux LM, Palomaki GE, Knight GJ, Haddow JE. Multiple marker screening for Down syndrome in twin pregnancies. Prenat Diagn. 1996; 16(1):29–34. PMID: 8821849.

23. Wald NJ, Rish S. Prenatal screening for Down syndrome and neural tube defects in twin pregnancies. Prenat Diagn. 2005; 25(9):740–745. PMID: 16170842.

24. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol. 2012; 119(5):890–901. PMID: 22362253.

25. Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014; 370(9):799–808. PMID: 24571752.

26. Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015; 372(17):1589–1597. PMID: 25830321.

27. Zhang H, Gao Y, Jiang F, Fu M, Yuan Y, Guo Y, et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound Obstet Gynecol. 2015; 45(5):530–538. PMID: 25598039.

28. Pergament E, Cuckle H, Zimmermann B, Banjevic M, Sigurjonsson S, Ryan A, et al. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol. 2014; 124(2 Pt 1):210–218. PMID: 25004354.

29. Snijders RJ, Sebire NJ, Nicolaides KH. Maternal age and gestational age-specific risk for chromosomal defects. Fetal Diagn Ther. 1995; 10(6):356–367. PMID: 8579773.

30. Benn P, Cuckle H, Pergament E. Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol. 2013; 42(1):15–33. PMID: 23765643.

31. Verweij EJ, de Boer MA, Oepkes D. Non-invasive prenatal testing for trisomy 13: more harm than good? Ultrasound Obstet Gynecol. 2014; 44(1):112–114. PMID: 24753041.

32. Mazloom AR, Džakula Ž, Oeth P, Wang H, Jensen T, Tynan J, et al. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. Prenat Diagn. 2013; 33(6):591–597. PMID: 23592550.

33. Samango-Sprouse C, Banjevic M, Ryan A, Sigurjonsson S, Zimmermann B, Hill M, et al. SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy. Prenat Diagn. 2013; 33(7):643–649. PMID: 23712453.

34. Nicolaides KH, Musci TJ, Struble CA, Syngelaki A, Gil MM. Assessment of fetal sex chromosome aneuploidy using directed cell-free DNA analysis. Fetal Diagn Ther. 2014; 35(1):1–6. PMID: 24335155.

35. Wang L, Meng Q, Tang X, Yin T, Zhang J, Yang S, et al. Maternal mosaicism of sex chromosome causes discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Taiwan J Obstet Gynecol. 2015; 54(5):527–531. PMID: 26522104.

36. Gregg AR, Skotko BG, Benkendorf JL, Monaghan KG, Bajaj K, Best RG, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2016; 18(10):1056–1065. PMID: 27467454.

37. Mennuti MT, Cherry AM, Morrissette JJ, Dugoff L. Is it time to sound an alarm about false-positive cell-free DNA testing for fetal aneuploidy? Am J Obstet Gynecol. 2013; 209(5):415–419. PMID: 23529082.

38. Willems PJ, Dierickx H, Vandenakker E, Bekedam D, Segers N, Deboulle K, et al. The first 3,000 non-invasive prenatal tests (NIPT) with the harmony test in Belgium and the Netherlands. Facts Views Vis ObGyn. 2014; 6(1):7–12. PMID: 25009720.

39. Committee Opinion No. Committee opinion No. 640: cell-free DNA screening for fetal aneuploidy. Obstet Gynecol. 2015; 126(3):e31–7. PMID: 26287791.

40. Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015; 372(17):1589–1597. PMID: 25830321.

41. Palomaki GE, Kloza EM. Prenatal cell-free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing. Genet Med. 2018; 20(11):1312–1323. PMID: 30514979.

42. Ashoor G, Syngelaki A, Poon LC, Rezende JC, Nicolaides KH. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013; 41(1):26–32. PMID: 23108725.

43. Statement SM. Society for Maternal-Fetal Medicine (SMFM) Publications Committee. SMFM Statement: clarification of recommendations regarding cell-free DNA aneuploidy screening. Am J Obstet Gynecol. 2015; 213(6):753–754. PMID: 26458766.

44. Baer RJ, Flessel MC, Jelliffe-Pawlowski LL, Goldman S, Hudgins L, Hull AD, et al. Detection rates for aneuploidy by first-trimester and sequential screening. Obstet Gynecol. 2015; 126(4):753–759. PMID: 26348180.

45. Norton ME, Jelliffe-Pawlowski LL, Currier RJ. Chromosome abnormalities detected by current prenatal screening and noninvasive prenatal testing. Obstet Gynecol. 2014; 124(5):979–986. PMID: 25437727.

46. Zimmermann B, Hill M, Gemelos G, Demko Z, Banjevic M, Baner J, et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn. 2012; 32(13):1233–1241. PMID: 23108718.

47. Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, Caughey AB, et al. Non-invasive chromosomal evaluation (NICE) study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012; 207(2):137.e1–137.e8. PMID: 22742782.

48. Wang E, Batey A, Struble C, Musci T, Song K, Oliphant A. Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenat Diagn. 2013; 33(7):662–666. PMID: 23553731.

49. del Mar Gil M, Quezada MS, Bregant B, Syngelaki A, Nicolaides KH. Cell-free DNA analysis for trisomy risk assessment in first-trimester twin pregnancies. Fetal Diagn Ther. 2014; 35(3):204–211. PMID: 24247435.

50. Bevilacqua E, Gil MM, Nicolaides KH, Ordoñez E, Cirigliano V, Dierickx H, et al. Performance of screening for aneuploidies by cell-free DNA analysis of maternal blood in twin pregnancies. Ultrasound Obstet Gynecol. 2015; 45(1):61–66. PMID: 25297464.

51. Sarno L, Revello R, Hanson E, Akolekar R, Nicolaides KH. Prospective first-trimester screening for trisomies by cell-free DNA testing of maternal blood in twin pregnancy. Ultrasound Obstet Gynecol. 2016; 47(6):705–711. PMID: 26970114.

52. Society for Maternal-Fetal Medicine (SMFM) Publications Committee. #36: Prenatal aneuploidy screening using cell-free DNA. Am J Obstet Gynecol. 2015; 212(6):711–716. PMID: 25813012.

53. Dar P, Curnow KJ, Gross SJ, Hall MP, Stosic M, Demko Z, et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. Am J Obstet Gynecol. 2014; 211(5):527.e1–527.e17. PMID: 25111587.